Article info
Miscellaneous
Journal club
GATA2, a novel therapeutic target for RAS-oncogene-addicted NSCLC?
- Correspondence to Dr Richard Lee, ST4 Specialty Trainee in Respiratory Medicine and General Internal Medicine, Darent Valley Hospital NHS Trust, Kent DA2 8DA, UK; richwlee{at}gmail.com
Citation
GATA2, a novel therapeutic target for RAS-oncogene-addicted NSCLC?
Publication history
- First published July 17, 2012.
Online issue publication
September 01, 2022
Article Versions
- Previous version (29 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions